These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30621568)

  • 1. New Frontiers in the Therapeutic Approach of Patients with Cardiovascular and Endocrine Diseases.
    Grande D; Terlizzese P; Gioia MI; Parisi G; Giagulli VA; Triggiani V; Iacoviello M
    Endocr Metab Immune Disord Drug Targets; 2019; 19(5):605-621. PubMed ID: 30621568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ
    Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Endocrinology in 2012: what's new?].
    Parrat D; Meyer P
    Rev Med Suisse; 2013 Jan; 9(368):36-9. PubMed ID: 23367701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevalence of thyroid dysfunction in patients with type 2 diabetes mellitus].
    Centeno Maxzud M; Gómez Rasjido L; Fregenal M; Arias Calafiore F; Córdoba Lanus M; D'Urso M; Luciardi H
    Medicina (B Aires); 2016; 76(6):355-358. PubMed ID: 27959843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subclinical thyroid dysfunction and cardiovascular outcomes among prospective cohort studies.
    Gencer B; Collet TH; Virgini V; Auer R; Rodondi N
    Endocr Metab Immune Disord Drug Targets; 2013 Mar; 13(1):4-12. PubMed ID: 23369133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subclinical hypothyroidism and cardiovascular risk: recommendations for treatment.
    Weiss IA; Bloomgarden N; Frishman WH
    Cardiol Rev; 2011; 19(6):291-9. PubMed ID: 21983317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk with subclinical hyperthyroidism and hypothyroidism: pathophysiology and management.
    Duggal J; Singh S; Barsano CP; Arora R
    J Cardiometab Syndr; 2007; 2(3):198-206. PubMed ID: 17786084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is subclinical hypothyroidism a cardiovascular risk factor in the elderly?
    Pasqualetti G; Tognini S; Polini A; Caraccio N; Monzani F
    J Clin Endocrinol Metab; 2013 Jun; 98(6):2256-66. PubMed ID: 23559085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid function, cardiovascular events, and mortality in diabetic hemodialysis patients.
    Drechsler C; Schneider A; Gutjahr-Lengsfeld L; Kroiss M; Carrero JJ; Krane V; Allolio B; Wanner C; Fassnacht M
    Am J Kidney Dis; 2014 Jun; 63(6):988-96. PubMed ID: 24315768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Changes in the cardiovascular system in selected endocrinopathies in children].
    Semeran K; Bossowski A
    Pediatr Endocrinol Diabetes Metab; 2011; 17(1):42-7. PubMed ID: 21489356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does treating subclinical hypothyroidism improve markers of cardiovascular risk?
    Monzani F; Dardano A; Caraccio N
    Treat Endocrinol; 2006; 5(2):65-81. PubMed ID: 16542047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiovascular consequences of thyroid diseases, their prevalence and treatment, particularly in cases with subclinical hyper- and hypothyroidism].
    Molnár I
    Orv Hetil; 2005 Oct; 146(40):2067-72. PubMed ID: 16259335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subclinical hypothyroidism and heart failure risk in older people.
    Pasqualetti G; Tognini S; Polini A; Caraccio N; Monzani F
    Endocr Metab Immune Disord Drug Targets; 2013 Mar; 13(1):13-21. PubMed ID: 23369134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease.
    Pantalone KM; Misra-Hebert AD; Hobbs TM; Ji X; Kong SX; Milinovich A; Weng W; Bauman J; Ganguly R; Burguera B; Kattan MW; Zimmerman RS
    Cardiovasc Diabetol; 2018 Apr; 17(1):54. PubMed ID: 29636104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for cardiovascular disease in subclinical hypothyroidism.
    Decandia F
    Ir J Med Sci; 2018 Feb; 187(1):39-43. PubMed ID: 28493136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral Antidiabetic Agents and Cardiovascular Outcomes.
    Pareek M; Bhatt DL
    Curr Probl Cardiol; 2018 Mar; 43(3):111-126. PubMed ID: 28844525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
    Thompson PL; Davis TME
    Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.